Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference48 articles.
1. Recent major improvement in long-term survival of younger patients with multiple myeloma;Brenner;Blood,2008
2. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008
3. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma;Lonial;Br J Haematol,2009
4. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma;San Miguel;N Engl J Med,2008
5. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group;Rajkumar;J Clin Oncol,2006
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cancers of the Blood;Fundamentals of Cancer Detection, Treatment, and Prevention;2022-05-13
2. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2020-12
3. Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma;Translational Cancer Research;2019-09
4. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma;The Cancer Journal;2019-01
5. Advancements in Nanomedicine for Multiple Myeloma;Trends in Molecular Medicine;2018-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3